Developments Ondine treats first patients in Phase 2 nasal photodisinfection trial Ondine Biomedical (LON:OBI) treated the first patients in its nasal photodisinfection exploratory Phase 2 trial to evaluate how effectively the treatment eradicates pathogens – Staphylococcus aureus – in the nose, and... February 7, 2022